Boston Scientific

2 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in in-stent restenosis, hepatocellular carcinoma. The ones with the nearest registered primary completion date still ahead:

• Jun 2027TheraSphere With Durvalumab and Tremelimumab for HCCPhase 2Active, not recruitingHepatocellular Carcinoma

2 trials have a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.

Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.

• A securities lawsuit naming the company as a defendant was filed on Mar 5, 2026 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.

  In re: Boston Scientific Corporation Securities Litigation, 1:26-cv-40075

• A securities lawsuit naming the company as a defendant was filed on Mar 5, 2026 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.

  Troike v. Boston Scientific Corporation, 4:26-cv-40075

Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). Coverage of court records is not complete, and shareholder derivative suits are not included.

36 certified in FY2026 Q3, vs 39 a year earlier. 36 positions in total, median offered wage $115K a year.

Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.

• Vanguard Capital Management

  Schedule 13G: passive · filed Apr 29, 2026 · 111M shares

  7.47%

Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.

23 approvals or clearances and 53 recalls recorded by the FDA for this company and its listed subsidiaries.

Approvals and clearances

• Sep 11SpaceOAR Flex™ SystemDevice clearance, 510(k)
• Sep 3Rezum SystemDevice clearance, 510(k)
• Aug 26LithoVue Elite Digital Flexible Ureteroscope SystemDevice clearance, 510(k)
• Aug 21AVVIGO™+ Multi-Modality Guidance SystemDevice clearance, 510(k)
• Aug 12EluPro Antibiotic-Eluting BioEnvelopeDevice clearance, 510(k)
• Aug 4Navigator™ Flex Ureteral Access Sheath SetDevice clearance, 510(k)
• Jul 24TheraSphere 360™ Y-90 Management PlatformDevice clearance, 510(k)
• Jul 24OBSIDIO Conformable EmbolicDevice clearance, 510(k)

Recalls

• Aug 24Imager II Angiographic Catheters M001314001 IMAGER II/5/ST/65/038 BX5; M001314011 IMAGER II/5/ST/100/038 BX5; M001314021 IMAGER II/5/ST/65/035 BX 5; M001314031…Class I · Ongoing · Tip may fracture or detach, leading to device fragments remaining within the patient or migrating through the vasculature. Patient impact may include prolonged procedure or life-threatening embolism.
• Aug 6LUX-Dx, LUX-Dx II, LUX-Dx II+ Insertable Cardiac Monitor System, SERVER SW LAT CLARITY DS US, Model Number 7260, All Versions (Current 7.8)Class II · Ongoing · There is potential for a delay in AF Burden Alert notification affecting the server software which supports the Insertable Cardiac Monitors (ICMs). Delayed notification of an AF Burden Alert may delay clinical evaluation or therapeutic intervention of an atrial arrhythmia.
• Aug 6LUX-Dx, LUX-Dx II, LUX-Dx II+ Insertable Cardiac Monitor System, SERVER SW LAT CLARITY DS ANZ, Model Number 7248, All Versions (Current 7.7)Class II · Ongoing · There is potential for a delay in AF Burden Alert notification affecting the server software which supports the Insertable Cardiac Monitors (ICMs). Delayed notification of an AF Burden Alert may delay clinical evaluation or therapeutic intervention of an atrial arrhythmia.

From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.

• Sep 23

  Top officer leaving

  “Butcher informed Boston Scientific Corporation (the “Company”) that he has decided to retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific effective as of January 1, 2027.”

  8-K on sec.gov
• Sep 8

  Disclosed a material cybersecurity incident

  8-K on sec.gov
• Sep 4

  Top officer leaving

  “Mirviss informed Boston Scientific Corporation (the “Company”) that he has decided to retire from his role as Executive Vice President and President, Peripheral Interventions effective as of December 1, 2025.”

  8-K on sec.gov

From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.